🇺🇸 FDA
Patent

US 9228014

Antibodies capable of blocking the interaction between CD48 and a CD48 receptor

granted A61KA61K2039/505A61P

Quick answer

US patent 9228014 (Antibodies capable of blocking the interaction between CD48 and a CD48 receptor) held by REGENERON PHARMACEUTICALS, INC. expires Mon Dec 31 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Jan 05 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 31 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61K, A61K2039/505, A61P, A61P1/00, A61P1/04